Owners, management and financials
CVR: 10007127
Secondary names: NOVO ENZYMES A/S, Chr. Hansen Holding A/S, Novonesis A/S
EUR 4,157,600,000
Revenue
Net result: EUR 583,600,000
Novo Holdings A/S (25-33,32%)
CVR · view owners
Ester Baiget Arnau, Rainer Chapour Lehmann
Board: Cornelis de Jong (chair) and 14 members
CVR · view management
Active
Founded 13 November 2000
CVR · view overview
2,629 employees
CVR · 2018
Owner registered: Novo Holdings A/S
CVR · 20/06/2024
View the full event history
NOVOZYMES A/S is a Danish company of the type Aktieselskab based in Bagsværd, founded in 2000. The company is registered under the industry Fremstilling af andre organiske basiskemikalier. The management consists of Ester Baiget Arnau and Rainer Chapour Lehmann. The board consists of Cornelis de Jong (chair), Heine Dalsgaard, Frederikke Rose Spenner and Kasim Kutay. The company is owned by Novo Holdings A/S. The company has 2,629 employees (2018). In 2025, the company reported revenue of EUR 4,157,600,000 and a net result of EUR 583,600,000 compared with EUR 305,800,000 the year before. Equity in the 2025 report amounted to EUR 10,855,200,000.
Source: annual report 2025, Danish Business Authority
NOVOZYMES A/S demonstrates strong financial health, with a solid equity position of €10.86 billion as of 2025. The company has shown a positive revenue trend, increasing from €3.83 billion in 2024 to €4.16 billion in 2025, alongside a significant rise in profit from €305.8 million to €583.6 million. The interim results for the first half of 2026 indicate continued growth, with revenue of €2.24 billion and profit of €370.8 million, surpassing the previous year's figures for the same period. With over 1,000 employees, NOVOZYMES holds a strong position in the organic basic chemicals industry, benefiting from healthy gross margins and a consistent upward trajectory in profitability.
AI-generated summary · Generated 21/08/2026
Selskabets formål er at drive forskning, udvikling, produktion og handel med biologiske løsninger, herunder enzymer, mikroorganismer og andre bioteknologiske processer og produkter samt drive virksomhed, der efter bestyrelsens nærmere bestemmelse står i forbindelse hermed. Selskabet tilstræber at drive sin virksomhed på bæredygtig og ansvarlig vis, herunder i økonomisk, miljømæssig og social henseende.
Source: annual reports filed with the Danish Business Authority.
| Period | Revenue | Profit/Loss | Total Assets | Equity | Employees | Report |
|---|---|---|---|---|---|---|
| 202501/01/2025 – 31/12/2025 | 4.2 mia. EUR | 583.6 mio. EUR | 16.3 mia. EUR | 10.9 mia. EUR | 11196 | |
| 202401/01/2024 – 31/12/2024 | 3.8 mia. EUR | 305.8 mio. EUR | 15.2 mia. EUR | 11.2 mia. EUR | 10208 | |
| 202301/01/2023 – 31/12/2023 | 17.9 mia. | 3 mia. | 28.4 mia. | 14.4 mia. | 6805 | |
| 202201/01/2022 – 31/12/2022 | 17.6 mia. | 3.7 mia. | 28 mia. | 14.2 mia. | 6690 | |
| 202101/01/2021 – 31/12/2021 | 15 mia. | 3.1 mia. | 24.8 mia. | 12.2 mia. | 6240 | |
| 202001/01/2020 – 31/12/2020 | 14 mia. | 2.8 mia. | 20.5 mia. | 11.2 mia. | 6099 | |
| 201901/01/2019 – 31/12/2019 | 14.4 mia. | 3.2 mia. | 20.4 mia. | 11.5 mia. | - | |
| 201801/01/2018 – 31/12/2018 | 14.4 mia. | 3.2 mia. | 19.7 mia. | 11.4 mia. | - | |
| 201701/01/2017 – 31/12/2017 | 14.5 mia. | 3.1 mia. | 18.4 mia. | 11.3 mia. | - | |
| 201601/01/2016 – 31/12/2016 | 14.1 mia. | 3 mia. | 18.7 mia. | 11.7 mia. | - | |
| 201501/01/2015 – 31/12/2015 | 14 mia. | 2.8 mia. | 17.8 mia. | 11.6 mia. | - | |
| 201401/01/2014 – 31/12/2014 | 12.5 mia. | 2.5 mia. | 18.4 mia. | 11.3 mia. | - |
Daily closing prices, Nasdaq Copenhagen
Compared to 14 companies in Fremstilling af andre organiske basiskemikalier
Comparison is based on industry median values
Screen owners and management against the Danish FSA's official PEP lists
23 properties
Upgrade to Pro to see addresses, building data and ownership details
Property report (PDF)
The entire property portfolio in one report: areas, usage, energy labels, flood exposure, planning zone and local plans.
See an example report (PDF)See the CDS score and get a full credit report with recommended credit limit and payment terms.
Read about the CDS scoreThe CVR number of NOVOZYMES A/S is 10007127.
NOVOZYMES A/S is owned by Novo Holdings A/S.
The management of NOVOZYMES A/S consists of Ester Baiget Arnau and Rainer Chapour Lehmann.
The board of NOVOZYMES A/S consists of Cornelis de Jong, Heine Dalsgaard and Frederikke Rose Spenner, with Cornelis de Jong as chair.
In 2025, NOVOZYMES A/S reported revenue of EUR 4,157,600,000.
NOVOZYMES A/S had 2,629 employees in 2018 according to the Danish CVR register.
Claim this page to add your logo and social links. Free to get started.
NOVOZYMES A/S has published its interim report for the period January 1, 2026 – June 30, 2026.
NOVOZYMES A/S has published its interim report for the period January 1, 2026 – March 31, 2026.
NOVOZYMES A/S has published its annual report for 2025. Revenue came to DKK 4,157,600,000, and the net result was DKK 583,600,000.
NOVOZYMES A/S has published its interim report for the period January 1, 2025 – September 30, 2025.
NOVOZYMES A/S has published its interim report for the period January 1, 2025 – June 30, 2025.
NOVOZYMES A/S has published its interim report for the period January 1, 2025 – March 31, 2025.
NOVOZYMES A/S has published its annual report for 2024. Revenue came to DKK 3,833,500,000, and the net result was DKK 305,800,000.
As of April 3, 2025, Mikael Barfred has joined the board of directors of NOVOZYMES A/S.
As of April 3, 2025, Lars Bo Køppler has joined the board of directors of NOVOZYMES A/S.
As of April 3, 2025, Heine Dalsgaard has joined the board of directors of NOVOZYMES A/S.
As of April 3, 2025, Heidi Gelt has joined the board of directors of NOVOZYMES A/S.
As of April 3, 2025, Robert Nøddeskov Jensen has joined the board of directors of NOVOZYMES A/S.
As of April 3, 2025, Monila Amar Kothari has joined the board of directors of NOVOZYMES A/S.
As of April 3, 2025, Frederikke Rose Spenner has joined the board of directors of NOVOZYMES A/S.
As of April 3, 2025, Ida Lam Virklund has joined the board of directors of NOVOZYMES A/S.
As of April 3, 2025, Niels Mortensen has left the board of directors of NOVOZYMES A/S.
As of April 3, 2025, Jesper Brandgaard has left the board of directors of NOVOZYMES A/S.
As of April 3, 2025, Anders Hentze Knudsen has left the board of directors of NOVOZYMES A/S.
As of April 3, 2025, Lena Bech Holskov has left the board of directors of NOVOZYMES A/S.
As of April 3, 2025, Jens Øbro has left the board of directors of NOVOZYMES A/S.
As of April 3, 2025, Jannik Bo Riis has left the board of directors of NOVOZYMES A/S.
As of April 2, 2025, Heine Dalsgaard has left the board of directors of NOVOZYMES A/S.
As of December 31, 2024, Sharon James has left the board of directors of NOVOZYMES A/S.
As of November 1, 2024, Lena Bech Holskov has joined the board of directors of NOVOZYMES A/S.
As of November 1, 2024, Anne Elme Breum has left the board of directors of NOVOZYMES A/S.
As of October 31, 2024, Lena Bech Holskov has left the board of directors of NOVOZYMES A/S.
NOVOZYMES A/S has published its interim report for the period January 1, 2024 – June 30, 2024.
As of June 20, 2024, Novo Holdings A/S is registered as an owner of NOVOZYMES A/S with an ownership share of 25%.
NOVOZYMES A/S has published its annual report for 2023. Revenue came to DKK 17,899,000,000, and the net result was DKK 3,039,000,000.
As of April 30, 2024, EY Godkendt Revisionspartnerselskab has been appointed auditor of NOVOZYMES A/S.
As of April 30, 2024, EY Godkendt Revisionspartnerselskab has been appointed auditor of NOVOZYMES A/S.
As of April 30, 2024, PRICEWATERHOUSECOOPERS STATSAUTORISERET REVISIONSPARTNERSELSKAB has stepped down as auditor of NOVOZYMES A/S.
As of March 4, 2024, Jesper Brandgaard has joined the board of directors of NOVOZYMES A/S.
As of March 4, 2024, Lise Kaae has joined the board of directors of NOVOZYMES A/S.
As of March 4, 2024, Kim Narelle Stratton has joined the board of directors of NOVOZYMES A/S.
As of March 4, 2024, Kevin Michael Lane has joined the board of directors of NOVOZYMES A/S.
As of March 3, 2024, Kim Narelle Stratton has left the board of directors of NOVOZYMES A/S.
As of November 1, 2023, Rainer Chapour Lehmann is registered as director of NOVOZYMES A/S.
As of November 1, 2023, Lars Green has stepped down as director of NOVOZYMES A/S.
NOVOZYMES A/S has published its interim report for the period January 1, 2023 – September 30, 2023.
NOVOZYMES A/S has published its interim report for the period January 1, 2023 – June 30, 2023.
NOVOZYMES A/S has published its interim report for the period January 1, 2023 – March 31, 2023.
NOVOZYMES A/S has published its annual report for 2022. Revenue came to DKK 17,553,000,000, and the net result was DKK 3,686,000,000.
As of March 2, 2023, Kim Narelle Stratton has joined the board of directors of NOVOZYMES A/S.
As of March 2, 2023, Cornelis de Jong has joined the board of directors of NOVOZYMES A/S.
As of March 2, 2023, Jørgen Buhl Rasmussen has left the board of directors of NOVOZYMES A/S.
As of March 1, 2023, Kim Narelle Stratton has left the board of directors of NOVOZYMES A/S.
As of March 1, 2023, Cornelis de Jong has left the board of directors of NOVOZYMES A/S.
NOVOZYMES A/S has published its interim report for the period January 1, 2022 – September 30, 2022.
NOVOZYMES A/S has published its interim report for the period January 1, 2022 – June 30, 2022.
NOVOZYMES A/S has published its annual report for 2021. Revenue came to DKK 14,951,000,000, and the net result was DKK 3,145,000,000.
NOVOZYMES A/S has published its interim report for the period January 1, 2022 – March 31, 2022.
As of March 16, 2022, Morten Otto Alexander Sommer has joined the board of directors of NOVOZYMES A/S.
As of March 16, 2022, Carl Erik Mathias Uhlén has left the board of directors of NOVOZYMES A/S.
NOVOZYMES A/S has published its interim report for the period January 1, 2021 – September 30, 2021.
NOVOZYMES A/S has published its interim report for the period January 1, 2021 – June 30, 2021.
NOVOZYMES A/S has published its interim report for the period January 1, 2021 – March 31, 2021.
As of March 31, 2021, Thomas Videbæk has stepped down as director of NOVOZYMES A/S.
NOVOZYMES A/S has published its annual report for 2020. Revenue came to DKK 14,012,000,000, and the net result was DKK 2,826,000,000.
As of March 11, 2021, Anne Elme Breum has joined the board of directors of NOVOZYMES A/S.
As of March 11, 2021, Lena Bech Holskov has joined the board of directors of NOVOZYMES A/S.
As of March 11, 2021, Preben Nielsen has joined the board of directors of NOVOZYMES A/S.
As of March 11, 2021, Jens Øbro has joined the board of directors of NOVOZYMES A/S.
As of March 11, 2021, Jannik Bo Riis has joined the board of directors of NOVOZYMES A/S.
As of March 11, 2021, Lars Bo Køppler has left the board of directors of NOVOZYMES A/S.
As of March 10, 2021, Anne Elme Breum has left the board of directors of NOVOZYMES A/S.
As of March 10, 2021, Lena Bech Holskov has left the board of directors of NOVOZYMES A/S.
As of March 10, 2021, Preben Nielsen has left the board of directors of NOVOZYMES A/S.
NOVOZYMES A/S has published its interim report for the period January 1, 2020 – September 30, 2020.
NOVOZYMES A/S has published its interim report for the period January 1, 2020 – June 30, 2020.
NOVOZYMES A/S has published its interim report for the period January 1, 2020 – March 31, 2020.
NOVOZYMES A/S has published its annual report for 2019. Revenue came to DKK 14,374,000,000, and the net result was DKK 3,155,000,000.
As of February 26, 2020, Heine Dalsgaard has joined the board of directors of NOVOZYMES A/S.
As of February 26, 2020, Sharon James has joined the board of directors of NOVOZYMES A/S.
As of February 26, 2020, Cornelis de Jong has joined the board of directors of NOVOZYMES A/S.
As of February 26, 2020, Agnete Raaschou-Nielsen has left the board of directors of NOVOZYMES A/S.
As of February 1, 2020, Ester Baiget Arnau is registered as adm. dir. of NOVOZYMES A/S.
As of February 1, 2020, Peder Holk Nielsen has stepped down as adm. dir. of NOVOZYMES A/S.
NOVOZYMES A/S has published its interim report for the period January 1, 2019 – September 30, 2019.
NOVOZYMES A/S has published its interim report for the period January 1, 2019 – June 30, 2019.
As of September 1, 2019, Lars Green is registered as director of NOVOZYMES A/S.
As of August 9, 2019, Lars Green has left the board of directors of NOVOZYMES A/S.
As of August 8, 2019, Prisca Havranek-Kosicek has stepped down as director of NOVOZYMES A/S.
NOVOZYMES A/S has published its interim report for the period January 1, 2019 – March 31, 2019.
NOVOZYMES A/S has published its annual report for 2018. Revenue came to DKK 14,390,000,000, and the net result was DKK 3,227,000,000.
As of January 31, 2019, Patricia Malarkey has left the board of directors of NOVOZYMES A/S.
NOVOZYMES A/S has published its interim report for the period January 1, 2018 – September 30, 2018.
NOVOZYMES A/S has published its interim report for the period January 1, 2018 – June 30, 2018.
NOVOZYMES A/S has published its interim report for the period January 1, 2018 – March 31, 2018.
NOVOZYMES A/S has published its annual report for 2017. Revenue came to DKK 14,531,000,000, and the net result was DKK 3,120,000,000.
As of March 13, 2018, Patricia Malarkey has joined the board of directors of NOVOZYMES A/S.
As of February 1, 2018, Prisca Havranek-Kosicek is registered as director of NOVOZYMES A/S.
NOVOZYMES A/S has published its interim report for the period January 1, 2017 – September 30, 2017.
NOVOZYMES A/S has published its interim report for the period January 1, 2017 – June 30, 2017.
As of August 10, 2017, Benny Dalgaard Loft has stepped down as director of NOVOZYMES A/S.
As of June 8, 2017, Heinz-Jürgen Bertram has left the board of directors of NOVOZYMES A/S.
NOVOZYMES A/S has published its interim report for the period January 1, 2017 – March 31, 2017.
NOVOZYMES A/S has published its annual report for 2016. Revenue came to DKK 14,142,000,000, and the net result was DKK 3,050,000,000.
As of February 22, 2017, Jørgen Buhl Rasmussen has joined the board of directors of NOVOZYMES A/S.
As of February 22, 2017, Agnete Raaschou-Nielsen has joined the board of directors of NOVOZYMES A/S.
As of February 22, 2017, Kasim Kutay has joined the board of directors of NOVOZYMES A/S.
As of February 22, 2017, Kim Narelle Stratton has joined the board of directors of NOVOZYMES A/S.
As of February 22, 2017, Preben Nielsen has joined the board of directors of NOVOZYMES A/S.
As of February 22, 2017, Henrik Gürtler has left the board of directors of NOVOZYMES A/S.
As of February 22, 2017, Niels Axel Stokholm Banke has left the board of directors of NOVOZYMES A/S.
As of February 21, 2017, Jørgen Buhl Rasmussen has left the board of directors of NOVOZYMES A/S.
As of February 21, 2017, Agnete Raaschou-Nielsen has left the board of directors of NOVOZYMES A/S.
NOVOZYMES A/S has published its interim report for the period January 1, 2016 – June 30, 2016.
NOVOZYMES A/S has published its interim report for the period January 1, 2016 – March 31, 2016.
NOVOZYMES A/S has published its annual report for 2015. Revenue came to DKK 14,002,000,000, and the net result was DKK 2,825,000,000.
As of February 24, 2016, Jørgen Buhl Rasmussen has joined the board of directors of NOVOZYMES A/S.
As of February 24, 2016, Agnete Raaschou-Nielsen has joined the board of directors of NOVOZYMES A/S.
As of February 24, 2016, Lena Marie Olving has left the board of directors of NOVOZYMES A/S.
As of February 23, 2016, Jørgen Buhl Rasmussen has left the board of directors of NOVOZYMES A/S.
As of February 23, 2016, Agnete Raaschou-Nielsen has left the board of directors of NOVOZYMES A/S.
As of February 8, 2016, Per Falholt has stepped down as director of NOVOZYMES A/S.
As of February 8, 2016, Thomas Geza Solyom Nagy has stepped down as director of NOVOZYMES A/S.
As of February 8, 2016, Andrew Patrick Fordyce has stepped down as director of NOVOZYMES A/S.
NOVOZYMES A/S has published its interim report for the period January 1, 2015 – September 30, 2015.
NOVOZYMES A/S has published its interim report for the period January 1, 2015 – June 30, 2015.
NOVOZYMES A/S has published its interim report for the period January 1, 2015 – March 31, 2015.
NOVOZYMES A/S has published its annual report for 2014. Revenue came to DKK 12,459,000,000, and the net result was DKK 2,525,000,000.
As of February 25, 2015, Heinz-Jürgen Bertram has joined the board of directors of NOVOZYMES A/S.
NOVOZYMES A/S has published its interim report for the period July 1, 2014 – September 30, 2014.
NOVOZYMES A/S has published its interim report for the period January 1, 2014 – June 30, 2014.
NOVOZYMES A/S has published its interim report for the period January 1, 2014 – March 31, 2014.
NOVOZYMES A/S has published its annual report for 2013.
As of February 26, 2014, Agnete Raaschou-Nielsen has joined the board of directors of NOVOZYMES A/S.
As of February 26, 2014, Lars Green has joined the board of directors of NOVOZYMES A/S.
As of February 26, 2014, Kurt Anker Nielsen has left the board of directors of NOVOZYMES A/S.
NOVOZYMES A/S has published its interim report for the period July 1, 2013 – September 30, 2013.
NOVOZYMES A/S has published its interim report for the period January 1, 2013 – June 30, 2013.
NOVOZYMES A/S has published its interim report for the period January 1, 2013 – March 31, 2013.
As of April 1, 2013, Peder Holk Nielsen is registered as adm. dir. of NOVOZYMES A/S.
As of April 1, 2013, Andrew Patrick Fordyce is registered as director of NOVOZYMES A/S.
As of April 1, 2013, Steen Riisgaard has stepped down as adm. dir. of NOVOZYMES A/S.
NOVOZYMES A/S has published its annual report for 2012.
As of February 28, 2013, Niels Mortensen has joined the board of directors of NOVOZYMES A/S.
As of February 28, 2013, Lars Bo Køppler has joined the board of directors of NOVOZYMES A/S.
As of February 28, 2013, Niels Axel Stokholm Banke has joined the board of directors of NOVOZYMES A/S.
As of February 28, 2013, Anne Elme Breum has joined the board of directors of NOVOZYMES A/S.
As of February 28, 2013, Anders Hentze Knudsen has joined the board of directors of NOVOZYMES A/S.
As of February 28, 2013, Lena Bech Holskov has joined the board of directors of NOVOZYMES A/S.
As of February 28, 2013, Søren Henrik Jepsen has left the board of directors of NOVOZYMES A/S.
As of February 28, 2013, Ulla Morin has left the board of directors of NOVOZYMES A/S.
As of February 28, 2013, Marianne Vind Petersen has left the board of directors of NOVOZYMES A/S.
As of February 29, 2012, Paul Petter Aas has left the board of directors of NOVOZYMES A/S.
As of July 1, 2011, PRICEWATERHOUSECOOPERS STATSAUTORISERET REVISIONSPARTNERSELSKAB has been appointed auditor of NOVOZYMES A/S.
As of July 1, 2011, A/S PSE NR. 4820 has stepped down as auditor of NOVOZYMES A/S.
As of March 2, 2011, Jørgen Buhl Rasmussen has joined the board of directors of NOVOZYMES A/S.
As of March 2, 2011, Lena Marie Olving has joined the board of directors of NOVOZYMES A/S.
As of March 2, 2011, Walther Thygesen has left the board of directors of NOVOZYMES A/S.
As of March 2, 2011, Jerker Hartwall has left the board of directors of NOVOZYMES A/S.
As of December 1, 2010, Lars Bo Køppler has left the board of directors of NOVOZYMES A/S.
As of December 1, 2010, Michael Munksø has left the board of directors of NOVOZYMES A/S.
As of March 4, 2009, Lars Bo Køppler has joined the board of directors of NOVOZYMES A/S.
As of March 4, 2009, Marianne Vind Petersen has joined the board of directors of NOVOZYMES A/S.
As of March 4, 2009, Michael Munksø has joined the board of directors of NOVOZYMES A/S.
As of March 4, 2009, Arne Hansen has left the board of directors of NOVOZYMES A/S.
As of March 4, 2009, Michael Munksø has left the board of directors of NOVOZYMES A/S.
As of March 4, 2009, Preben Kurt Rasmussen has left the board of directors of NOVOZYMES A/S.
As of October 31, 2008, Hans Kristian Werdelin has left the board of directors of NOVOZYMES A/S.
As of October 31, 2008, Nomi Elise Skovgaard has left the board of directors of NOVOZYMES A/S.
As of October 1, 2007, Thomas Geza Solyom Nagy is registered as director of NOVOZYMES A/S.
As of October 1, 2007, Thomas Videbæk is registered as director of NOVOZYMES A/S.
As of October 1, 2007, Arne Wintherhalter Schmidt has stepped down as director of NOVOZYMES A/S.
As of March 8, 2007, Carl Erik Mathias Uhlén has joined the board of directors of NOVOZYMES A/S.
As of December 6, 2006, Benny Dalgaard Loft is registered as director of NOVOZYMES A/S.
As of November 22, 2006, Per Artur Fredrik Månsson has stepped down as director of NOVOZYMES A/S.
As of March 1, 2006, A/S PSE NR. 4820 has been appointed auditor of NOVOZYMES A/S.
As of March 1, 2006, A/S PSE NR. 4820 has been appointed auditor of NOVOZYMES A/S.
As of March 1, 2006, A/S PSE NR. 4820 has stepped down as auditor of NOVOZYMES A/S.
As of March 1, 2006, Pricewaterhouse Coopers has stepped down as auditor of NOVOZYMES A/S.
As of March 18, 2005, EY Danmark A/S has been appointed auditor of NOVOZYMES A/S.
As of March 18, 2005, EY Danmark A/S has stepped down as auditor of NOVOZYMES A/S.
As of March 16, 2005, EY Danmark A/S has stepped down as auditor of NOVOZYMES A/S.
As of March 16, 2005, Søren Henrik Jepsen has joined the board of directors of NOVOZYMES A/S.
As of March 16, 2005, Michael Munksø has joined the board of directors of NOVOZYMES A/S.
As of March 16, 2005, Preben Kurt Rasmussen has joined the board of directors of NOVOZYMES A/S.
As of March 16, 2005, Jens Nielsen has left the board of directors of NOVOZYMES A/S.
As of March 16, 2005, Lars Bo Køppler has left the board of directors of NOVOZYMES A/S.
As of September 1, 2001, Lars Bo Køppler has joined the board of directors of NOVOZYMES A/S.
As of September 1, 2001, Lars Bo Køppler has left the board of directors of NOVOZYMES A/S.
As of September 1, 2001, Thomas Sandal has left the board of directors of NOVOZYMES A/S.
As of March 21, 2001, Nomi Elise Skovgaard has joined the board of directors of NOVOZYMES A/S.
As of March 21, 2001, Jens Nielsen has joined the board of directors of NOVOZYMES A/S.
As of March 21, 2001, Ulla Morin has joined the board of directors of NOVOZYMES A/S.
As of March 21, 2001, Lars Bo Køppler has joined the board of directors of NOVOZYMES A/S.
As of March 21, 2001, Arne Hansen has joined the board of directors of NOVOZYMES A/S.
As of March 21, 2001, Thomas Sandal has joined the board of directors of NOVOZYMES A/S.
As of November 13, 2000, EY Danmark A/S has been appointed auditor of NOVOZYMES A/S.
As of November 13, 2000, Pricewaterhouse Coopers has been appointed auditor of NOVOZYMES A/S.
As of November 13, 2000, Kurt Anker Nielsen has joined the board of directors of NOVOZYMES A/S.
As of November 13, 2000, Hans Kristian Werdelin has joined the board of directors of NOVOZYMES A/S.
As of November 13, 2000, Walther Thygesen has joined the board of directors of NOVOZYMES A/S.
As of November 13, 2000, Henrik Gürtler has joined the board of directors of NOVOZYMES A/S.
As of November 13, 2000, Paul Petter Aas has joined the board of directors of NOVOZYMES A/S.
As of November 13, 2000, Jerker Hartwall has joined the board of directors of NOVOZYMES A/S.
As of November 13, 2000, Steen Riisgaard is registered as adm. dir. of NOVOZYMES A/S.
As of November 13, 2000, Per Falholt is registered as director of NOVOZYMES A/S.
As of November 13, 2000, Arne Wintherhalter Schmidt is registered as director of NOVOZYMES A/S.
As of November 13, 2000, Per Artur Fredrik Månsson is registered as director of NOVOZYMES A/S.
NOVOZYMES A/S was founded on November 13, 2000.
14 news items and press releases
Sources: Via Ritzau and Danish news media. Links open at the source.
